PGEN - Precigen Inc Stock Price, Fair Value and News

1.33USD+0.02 (+1.53%)Market Closed

Market Summary

USD1.33+0.02

Market Closed

1.53%

PGEN Stock Price

View Fullscreen

PGEN RSI Chart

PGEN Valuation

Market Cap

331.1M

Price/Earnings (Trailing)

-3.45

Price/Sales (Trailing)

16.22

EV/EBITDA

-3.65

Price/Free Cashflow

-4.84

PGEN Price/Sales (Trailing)

PGEN Profitability

EBT Margin

-435.97%

Return on Equity

-80.93%

Return on Assets

-63.49%

Free Cashflow Yield

-20.68%

PGEN Fundamentals

PGEN Revenue

Revenue (TTM)

22.1M

Rev. Growth (Yr)

-39.3%

Rev. Growth (Qtr)

-4.54%

PGEN Earnings

Earnings (TTM)

-95.9M

Earnings Growth (Yr)

-49.06%

Earnings Growth (Qtr)

-66.99%

Breaking Down PGEN Revenue

Last 7 days

-8.3%

Last 30 days

-7.6%

Last 90 days

3.9%

Trailing 12 Months

14.7%

How does PGEN drawdown profile look like?

PGEN Financial Health

Current Ratio

2.99

PGEN Investor Care

Buy Backs (1Y)

1.30%

Diluted EPS (TTM)

-0.39

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	23.2M	22.1M	0	0
2022	16.3M	15.4M	28.8M	26.9M
2021	97.9M	71.2M	51.0M	35.3M
2020	98.0M	95.6M	100.8M	103.2M
2019	134.1M	121.7M	107.5M	90.7M
2018	217.1M	208.0M	194.4M	151.2M
2017	201.2M	203.2M	200.2M	231.2M
2016	183.2M	190.8M	186.4M	190.9M
2015	97.9M	131.0M	163.2M	173.6M
2014	27.7M	32.8M	48.0M	71.9M
2013	16.1M	20.1M	23.2M	23.8M
2012	9.5M	10.9M	12.3M	13.8M
2011	0	0	0	8.0M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Precigen Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 05, 2024	perez jeffrey thomas	sold (taxes)	-61,878	1.4	-44,199	svp, ip affairs
Apr 05, 2024	shah rutul r	sold (taxes)	-57,218	1.4	-40,870	chief operating officer
Apr 05, 2024	lehr donald p.	acquired	-	-	164,285	chief legal officer
Apr 05, 2024	thomasian harry jr.	sold (taxes)	-94,344	1.4	-67,389	chief financial officer
Apr 05, 2024	thomasian harry jr.	acquired	-	-	135,714	chief financial officer
Apr 05, 2024	sabzevari helen	acquired	-	-	1,071,430	president and ceo
Apr 05, 2024	lehr donald p.	sold (taxes)	-77,105	1.4	-55,075	chief legal officer
Apr 05, 2024	perez jeffrey thomas	acquired	-	-	142,857	svp, ip affairs
Apr 05, 2024	sabzevari helen	sold (taxes)	-574,500	1.4	-410,357	president and ceo
Apr 05, 2024	shah rutul r	acquired	-	-	117,142	chief operating officer

Which funds bought or sold PGEN recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 15, 2024	EXCHANGE TRADED CONCEPTS, LLC	added	111	162,838	288,920	0.01%
Apr 15, 2024	Sound Income Strategies, LLC	new	-	1,291	1,291	-%
Apr 12, 2024	Flower City Capital	sold off	-100	-13,400	-	-%
Apr 12, 2024	HARBOR INVESTMENT ADVISORY, LLC	unchanged	-	13.00	181	-%
Apr 12, 2024	AdvisorNet Financial, Inc	reduced	-5.75	46.00	2,378	-%
Apr 11, 2024	SANDERS MORRIS HARRIS LLC	new	-	1,022,250	1,022,250	0.19%
Apr 11, 2024	Roble, Belko & Company, Inc	unchanged	-	-	-	-%
Apr 10, 2024	LexAurum Advisors, LLC	reduced	-8.8	-1,715	129,291	0.03%
Apr 05, 2024	GAMMA Investing LLC	unchanged	-	14.00	296	-%
Apr 05, 2024	CWM, LLC	unchanged	-	4,000	62,000	-%

Are Funds Buying or Selling PGEN?

Are funds buying PGEN calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own PGEN

No. of Funds

Unveiling Precigen Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 27, 2024	patient capital management, llc	6.42%	15,983,700	SC 13G/A
Feb 14, 2024	ares trading s.a.	8.3%	20,647,152	SC 13G/A
Feb 14, 2024	patient capital management, llc	6.42%	15,983,700	SC 13G
Jan 31, 2023	kirk randal j	38.3%	96,360,443	SC 13D/A
Jan 27, 2023	ares trading s.a.	9.92%	20,647,152	SC 13G/A
Oct 07, 2022	kirk randal j	40.7%	84,805,277	SC 13D/A
Jan 24, 2022	ares trading s.a.	9.99%	20,647,152	SC 13G/A
Feb 16, 2021	miller value partners, llc	3.85%	7,134,094	SC 13G/A
Jan 08, 2021	ares trading s.a.	14.8%	27,398,519	SC 13G/A
Dec 21, 2020	kirk randal j	43.6%	81,822,163	SC 13D/A

Recent SEC filings of Precigen Inc

View All Filings

Date Filed	Form Type	Document
Apr 09, 2024	4	Insider Trading
Apr 09, 2024	4	Insider Trading
Apr 09, 2024	4	Insider Trading
Apr 09, 2024	4	Insider Trading
Apr 09, 2024	4	Insider Trading
Mar 19, 2024	10-K	Annual Report
Mar 19, 2024	8-K	Current Report
Mar 18, 2024	4	Insider Trading
Mar 18, 2024	4	Insider Trading
Mar 18, 2024	4	Insider Trading

Peers (Alternatives to Precigen Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	39.0B	6.8B	-2.93%	-28.56%	-8.27	5.69	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.3B	1.8B	-2.14%	-28.32%	-41.48	9.99	76.23%	61.08%
BMRN	17.0B	2.4B	5.64%	-9.07%	101.38	7.03	15.42%	18.43%
INCY	11.9B	3.7B	-9.46%	-28.45%	19.84	3.21	8.87%	75.42%
MID-CAP
APLS	5.7B	396.6M	-16.55%	-42.15%	-10.83	14.44	425.83%	18.94%
BBIO	4.4B	-	-12.14%	49.76%	-6.72	60.35	54.84%	-34.79%
AXSM	3.1B	270.6M	-14.48%	-8.88%	-13.02	11.51	440.80%	-27.84%
ACAD	2.8B	726.4M	-8.72%	-14.74%	-45.89	3.87	40.45%	71.62%
ARWR	2.8B	240.7M	-18.65%	-25.84%	-9.43	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-6.41%	-11.48%	25.32	4.54	85.90%	-14.05%
NVAX	544.4M	983.7M	-21.26%	-56.58%	-1	0.55	-50.36%	17.16%
CRBP	382.8M	881.7K	-14.69%	262.26%	-8.58	466.16	-77.61%	-5.33%
INO	238.4M	4.9M	-4.49%	-3.41%	-1.76	48.98	-54.97%	51.71%
IBIO	6.2M	2.1M	67.92%	36.92%	-0.23	2.14	-13.45%	66.37%

Precigen Inc News

Latest updates

Precigen Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2
Revenue	-4.5%	1,767,000	1,851,000	1,763,000	16,722,000	2,911,000	5,513,000	3,684,000	3,333,000	3,815,000	24,511,000	19,333,000	23,583,000	30,424,000	29,838,000	17,002,000	18,299,000	32,836,000	22,585,000	33,789,000	32,448,000	45,275,000
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	92,000	-37,480,500	2,480,000	2,200,000	82,038,000	-273,472,500	98,919,000	95,010,000
S&GA Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	24,741,000	21,483,000	33,594,000	24,935,000	38,708,000	34,427,000
R&D Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	31,480,000	34,518,000	33,062,000	280,449,500	44,885,000	42,049,000
EBITDA Margin	0.8%	-2.78	-2.80	-2.31	-2.45	-5.59	-5.40	-2.43	-1.91	-1.36	-0.82	-	-	-	-	-	-	-	-	-	-	-
Interest Expenses	-85.3%	136,000	924,000	624,500	2,036,000	2,063,000	3,535,000	-2,871,500	4,765,000	4,633,000	3,539,000	-2,778,500	4,646,000	4,592,000	3,568,000	-2,546,000	4,466,000	4,353,000	77,000	-372,000	3,999,000	142,000
Income Taxes	-18.2%	-65,000	-55,000	8,000	-50,000	-89,000	-58,000	-164,000	-	-	4,000	-130,000	8,000	-	40,000	-451,500	-512,000	-525,000	30,000	4,110,000	-14,322,000	-1,127,000
Earnings Before Taxes	10.6%	-20,384,000	-22,789,000	-22,168,000	-7,694,000	-26,148,000	-23,956,000	-29,188,500	-26,380,000	-30,999,000	-21,896,000	-40,303,000	-27,586,000	-15,829,000	-20,806,000	-36,980,000	-49,057,000	-32,314,000	-52,913,000	-203,393,000	-73,068,000	-67,956,000
EBT Margin	2.5%	-3.30	-3.39	-2.97	-3.02	-6.84	-6.76	-3.07	-2.35	-1.70	-1.08	-	-	-	-	-	-	-	-	-	-	-
Net Income	10.6%	-20,319,000	-22,734,000	-22,176,000	87,379,000	-17,635,000	-19,251,000	-25,034,000	-29,764,000	-20,050,000	-17,318,000	-41,661,000	-29,508,000	-43,354,000	-55,998,000	-169,215,000	-53,634,000	-38,766,000	-60,709,000	-340,465,000	-57,324,000	-65,382,000
Net Income Margin	-6.2%	1.00	1.07	1.05	0.88	-5.94	-5.76	-2.61	-2.13	-1.52	-1.35	-	-	-	-	-	-	-	-	-	-	-
Free Cashflow	14.4%	-15,869,000	-18,542,000	-15,449,000	-25,387,000	-8,771,000	-20,362,000	-17,362,000	-19,288,000	-8,970,000	-17,398,000	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-20.8%	151	191	208	242	216	259	321	336	360	377	403	407	315	336	362	405	456	605	655	710	716
Current Assets	-26.1%	69.00	93.00	106	138	118	163	165	155	157	153	157	144	149	151	173	189	235	157	183	232	285
Cash Equivalents	-24.8%	8.00	10.00	17.00	10.00	5.00	92.00	50.00	41.00	43.00	42.00	37.00	28.00	52.00	28.00	47.00	38.00	68.00	45.00	59.00	107	110
Net PPE	-0.1%	7.00	7.00	7.00	7.00	7.00	8.00	8.00	34.00	9.00	33.00	33.00	34.00	35.00	45.00	47.00	60.00	44.00	123	120	136	87.00
Goodwill	-27.9%	27.00	37.00	37.00	37.00	37.00	37.00	37.00	54.00	38.00	54.00	54.00	54.00	38.00	54.00	54.00	64.00	54.00	148	150	151	84.00
Liabilities	-24.3%	33.00	43.00	41.00	57.00	90.00	117	266	262	253	246	243	232	247	278	312	317	384	376	376	375	337
Current Liabilities	-30.1%	23.00	33.00	31.00	47.00	79.00	105	30.00	26.00	35.00	29.00	29.00	25.00	42.00	31.00	64.00	71.00	123	82.00	52.00	59.00	62.00
Short Term Borrowings	-	-	-	-	14.00	43.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Long Term Debt	-	-	-	-	-	-	-	199	201	180	180	177	174	172	194	191	189	186	184	212	214	211
LT Debt, Current	-	-	-	-	-	43.00	82.00	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00	32.00	32.00	32.00	31.00	0.00	1.00	0.00
LT Debt, Non Current	-	-	-	-	-	-	-	199	201	180	180	177	174	172	194	191	189	186	184	212	214	211
Shareholder's Equity	-19.8%	118	148	166	184	126	143	56.00	74.00	107	131	159	175	67.00	59.00	50.00	87.00	72.00	228	279	335	379
Retained Earnings	-1.7%	-1,964	-1,931	-1,911	-1,891	-1,868	-1,846	-1,933	-1,916	-1,915	-1,890	-1,860	-1,840	-1,823	-1,781	-1,752	-1,708	-1,652	-1,483	-1,430	-1,391	-1,330
Additional Paid-In Capital	0.1%	2,085	2,083	2,080	2,078	1,998	1,996	1,994	1,992	2,023	2,020	2,017	2,014	1,887	1,839	1,802	1,797	1,752	1,745	1,737	1,733	1,722
Shares Outstanding	-2.9%	249	256	255	255	208	201	200	200	198	199	199	-	-	-	-	-	-	-	-	-	-
Minority Interest	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	22.00	16.00
Float	-	-	-	177	-	-	-	162	-	-	-	790	-	-	-	435	-	-	-	660	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	7.3%	-15,766	-17,008	-15,768	-18,388	-15,396	-23,813	-7,053	-18,783	-14,589	-17,022	-7,776	-16,384	-16,469	-19,004	-13,805	-27,743	-32,142	-27,148	-33,403	-43,234	-37,362
Share Based Compensation	-1.9%	2,262	2,306	2,189	3,131	2,210	2,125	2,309	3,562	2,442	2,490	3,557	5,415	4,497	4,600	4,897	4,372	4,412	5,423	61.00	9,054	7,956
Cashflow From Investing	26.3%	13,293	10,525	23,503	-50,408	11,421	181,855	16,573	16,568	15,929	22,013	16,620	-129,102	40,184	181	23,967	-36,553	54,509	13,777	-15,027	33,592	30,741
Cashflow From Financing	-	-	-	-14,585	44,174	-39,282	-115,734	-113	-163	-110	234	23.00	121,040	-72.00	-114	-1,260	34,151	1,199	45.00	-33.00	6,927	27,249

PGEN Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Operating Expenses
Impairment of goodwill	$ 10,390	$ 482	$ 0
Impairment of other noncurrent assets	445	638	543
Other Income (expense), Net
Equity in net income (loss) of affiliates	0	862	(3)
Loss from continuing operations before income taxes	(96,362)	(79,966)	(110,967)
Income tax benefit	458	189	160
Income from discontinued operations, net of income tax benefit	0	108,094	18,641
Net loss attributable to Precigen	$ (95,904)	$ 28,317	$ (92,166)
Net (Loss) Income per Share
Net loss from continuing operations per share, basic (in usd per share)	$ (0.39)	$ (0.40)	$ (0.56)
Net loss from continuing operations per share, diluted (in usd per share)	(0.39)	(0.40)	(0.56)
Net income from discontinued operations per share, basic (in usd per share)	0.00	0.54	0.09
Net income from discontinued operations per share, diluted (in usd per share)	0.00	0.54	0.09
Net (loss) income per share, diluted (in usd per share)	(0.39)	0.14	(0.47)
Net (loss) income per share, basic (in usd per share)	$ (0.39)	$ 0.14	$ (0.47)
Weighted average shares outstanding, basic (in shares)	244,536,221	200,360,821	197,759,900
Weighted average shares outstanding, diluted (in shares)	244,536,221	200,360,821	197,759,900
Collaboration and licensing agreements
Revenues
Revenues	$ 75	$ 14,661	$ 506
Continuing Operations
Revenues
Revenues	6,225	26,909	14,267
Operating Expenses
Research and development	48,614	47,170	47,933
Selling, general and administrative	40,415	48,006	51,994
Impairment of goodwill	10,390	482	0
Impairment of other noncurrent assets	445	638	543
Total operating expenses	105,983	102,635	106,215
Operating loss	(99,758)	(75,726)	(91,948)
Other Income (expense), Net
Interest expense	(468)	(6,774)	(18,755)
Interest income	3,237	133	171
Other income (expense), net	627	1,539	(432)
Total other income (expense), net	3,396	(5,102)	(19,016)
Equity in net income (loss) of affiliates	0	862	(3)
Loss from continuing operations before income taxes	(96,362)	(79,966)	(110,967)
Income tax benefit	458	189	160
Loss from continuing operations	(95,904)	(79,777)	(110,807)
Continuing Operations \| Collaboration and licensing agreements
Revenues
Revenues	75	14,661	506
Continuing Operations \| Product revenues
Revenues
Revenues	840	1,903	2,164
Continuing Operations \| Service revenues
Revenues
Revenues	5,301	10,094	11,095
Operating Expenses
Cost of product and services	6,119	6,339	5,745
Continuing Operations \| Other revenues
Revenues
Revenues	$ 9	$ 251	$ 502

PGEN Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 7,578,000	$ 4,858,000
Restricted cash	0	43,339,000
Short-term investments	55,277,000	51,092,000
Receivables
Trade, less allowance for credit losses of $184 as of both December 31, 2023 and 2022	902,000	978,000
Other	673,000	12,826,000
Prepaid expenses and other	4,325,000	5,066,000
Total current assets	68,755,000	118,159,000
Property, plant and equipment, net	7,111,000	7,329,000
Intangible assets, net	40,701,000	44,455,000
Goodwill	26,612,000	36,923,000
Right-of-use assets	7,097,000	8,086,000
Other assets	767,000	1,025,000
Total assets	151,043,000	215,977,000
Current liabilities
Accounts payable	1,726,000	4,068,000
Accrued compensation and benefits	8,250,000	6,377,000
Other accrued liabilities	6,223,000	4,997,000
Settlement and indemnification accrual	5,075,000	18,750,000
Deferred revenue	509,000	25,000
Current portion of long-term debt	0	43,219,000
Current portion of lease liabilities	1,202,000	1,209,000
Total current liabilities	22,985,000	78,645,000
Long-term portion of deferred revenue	1,818,000	1,818,000
Lease liabilities, net of current portion	5,895,000	6,992,000
Deferred tax liabilities	1,847,000	2,263,000
Total liabilities	32,545,000	89,718,000
Commitments and Contingencies
Shareholders' equity
Common stock, no par value, 400,000,000 shares authorized as of December 31, 2023 and 2022; 256,398,527 shares and 208,150,021 shares issued as of December 31, 2023 and 2022, 248,919,096 shares and 208,150,021 shares outstanding December 31, 2023 and 2022, respectively.	0	0
Additional paid-in capital	2,084,916,000	1,998,314,000
Accumulated deficit	(1,964,471,000)	(1,868,567,000)
Accumulated other comprehensive loss	(1,947,000)	(3,488,000)
Total shareholders' equity	118,498,000	126,259,000
Total liabilities and shareholders' equity	$ 151,043,000	$ 215,977,000
Common stock, shares outstanding (in shares)	248,919,096	208,150,021

About Precigen Inc

Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. The company operates through two segments, Biopharmaceuticals and Exemplar. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and Lactococcus lactis, a food-grade bacterium. Additionally, it provides RheoSwitch Therapeutic System, an inducible gene switch system that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; tissue-specific promoters; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with Alaunos Therapeutics, Inc.; Intrexon Energy Partners, LLC; and Intrexon Energy Partners II, LLC. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.

CEO	Dr. Helen Sabzevari MPH, Ph.D.
WEBSITE	https://precigen.com
INDUSTRY	Biotechnology
EMPLOYEES	209

Precigen Inc Frequently Asked Questions

What is the ticker symbol for Precigen Inc? What does PGEN stand for in stocks?

PGEN is the stock ticker symbol of Precigen Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Precigen Inc (PGEN)?

As of Thu Apr 18 2024, market cap of Precigen Inc is 331.06 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PGEN stock?

You can check PGEN's fair value in chart for subscribers.

What is the fair value of PGEN stock?

You can check PGEN's fair value in chart for subscribers. The fair value of Precigen Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Precigen Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for PGEN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Precigen Inc a good stock to buy?

The fair value guage provides a quick view whether PGEN is over valued or under valued. Whether Precigen Inc is cheap or expensive depends on the assumptions which impact Precigen Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PGEN.

What is Precigen Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Apr 18 2024, PGEN's PE ratio (Price to Earnings) is -3.45 and Price to Sales (PS) ratio is 16.22. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PGEN PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Precigen Inc's stock?

In the past 10 years, Precigen Inc has provided -0.235 (multiply by 100 for percentage) rate of return.